Summary:
- SNIPR BIOME, a company based in Copenhagen, Denmark, has secured EUR 35M in Series B funding to advance microbial CRISPR-medicine development.
- The funding round included support from the Cystic Fibrosis Foundation, the German Federal Agency for Breakthrough Innovation, and existing investors.
- SNIPR Biome aims to use the funds to progress the development of a CRISPR-Cas therapy for airway infections in individuals with cystic fibrosis caused by Pseudomonas aeruginosa.
Article:
Empowering Microbial CRISPR-Medicine Development: SNIPR BIOME Secures EUR 35M in Series B Funding
SNIPR BIOME, a pioneering company hailing from Copenhagen, Denmark, has recently announced a significant milestone in its journey towards enhancing microbial CRISPR-medicine development. The company successfully raised EUR 35 million in Series B funding, marking a substantial step forward in its mission to revolutionize the field.
The funding round saw the participation of notable backers, including the Cystic Fibrosis Foundation, the German Federal Agency for Breakthrough Innovation (SPRIN-D), alongside existing investors such as Lundbeckfonden BioCapital, North-East Family Office, and Wellington Partners. This diverse pool of support underscores the industry’s recognition of SNIPR BIOME’s innovative approach and potential impact.
Specifically, SNIPR BIOME plans to allocate the funds towards advancing the development of a CRISPR-Cas therapy tailored to target airway infections linked to Pseudomonas aeruginosa in individuals affected by cystic fibrosis (CF). By focusing on precision killing of bacteria through CRISPR technology, the company aims to address a critical unmet need in the treatment landscape.
Led by CEO Christian Grøndahl, SNIPR BIOME stands out as a clinical-stage biotech firm dedicated to harnessing the power of CRISPR-medicine. Through its unique utilization of CRISPR-Cas technology, the company strives to innovate treatment modalities and preventive strategies for various human diseases, leveraging the precision of gene modification and bacterial eradication.
Furthermore, SNIPR BIOME’s technology collaborations with renowned entities such as CARB-X, Gates Foundation, Cystic Fibrosis Foundation, IPATH, SPRIN-D, and MD Anderson Cancer Center underscore its commitment to driving impactful advancements in the healthcare sector. With a focus on leveraging CRISPR technology to tackle complex health challenges, SNIPR BIOME is poised to make a significant difference in the realm of microbial CRISPR-medicine development.
In conclusion, SNIPR BIOME’s recent funding achievement not only highlights the company’s growth trajectory but also signifies a pivotal moment in advancing microbial CRISPR-medicine innovation. With a dedicated team and a clear vision, SNIPR BIOME is well-positioned to shape the future of precision healthcare through its groundbreaking approach.
Published by FinSMEs on 07/08/2025
